To the editor: Imatinib dosing in patients with chronic myeloid leukemia (CML) is flat, as pharmacokinetic (PK) studies showed that plasma trough concentrations are correlated with dose, whereas body weight or body surface area are of minor importance.[1][1],[2][2] However, there is considerable
No takes yet. Share an insight, caveat, or question.
Blasdel et al. (2007) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: